Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:actsOn |
REV-ERB agonist
|
| gptkbp:administeredBy |
injection
oral |
| gptkbp:alsoKnownAs |
gptkb:Stenabolic
|
| gptkbp:CASNumber |
1379686-30-2
|
| gptkbp:category |
research chemical
performance-enhancing drug (investigational) nuclear receptor ligand |
| gptkbp:chemicalFormula |
C20H24ClN3O4S
|
| gptkbp:compatibleWith |
gptkb:FDA
gptkb:EMA human consumption |
| gptkbp:developedBy |
gptkb:Scripps_Research_Institute
|
| gptkbp:effectInMice |
altered circadian behavior
altered lipid and glucose metabolism increased exercise endurance reduced fat mass |
| https://www.w3.org/2000/01/rdf-schema#label |
SR 902
|
| gptkbp:legalStatus |
unregulated (research chemical)
|
| gptkbp:mechanismOfAction |
modulates REV-ERB nuclear receptors
|
| gptkbp:relatedTo |
SR9009
|
| gptkbp:studiedBy |
metabolic disorders
circadian rhythm regulation potential athletic performance enhancement |
| gptkbp:target |
NR1D1 (REV-ERBα)
NR1D2 (REV-ERBβ) |
| gptkbp:usedIn |
scientific research
|
| gptkbp:bfsParent |
gptkb:State_Route_902
|
| gptkbp:bfsLayer |
8
|